Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.33 USD | -7.08% | -48.02% | -82.58% |
10/05 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
10/05 | Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4 | MT |
Business Summary
Number of employees: 131
Managers
Managers | Title | Age | Since |
---|---|---|---|
Brian Wong
CEO | Chief Executive Officer | 52 | 01/15/01 |
Rodney Young
DFI | Director of Finance/CFO | 61 | 02/19/02 |
Jim Farmer
CTO | Chief Tech/Sci/R&D Officer | - | 04/22/04 |
William Ho
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/15/01 |
Dirk Brockstedt
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/18/01 |
Nipun Davar
CTO | Chief Tech/Sci/R&D Officer | - | 13/02 |
Investor Relations Contact | 63 | - | |
General Counsel | - | 03/23/03 | |
Adnan Rahman
PRN | Corporate Officer/Principal | - | 28/22/28 |
Shari L. Geffon
PRN | Corporate Officer/Principal | - | 04/22/04 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mary Gray
BRD | Director/Board Member | 71 | 04/19/04 |
William Rieflin
CHM | Chairman | 64 | 01/15/01 |
Wendye Robbins
BRD | Director/Board Member | 63 | 22/19/22 |
Brian Wong
CEO | Chief Executive Officer | 52 | 01/15/01 |
Michael Giordano
BRD | Director/Board Member | 66 | 01/18/01 |
Linda Kozick
BRD | Director/Board Member | 66 | 01/16/01 |
Director/Board Member | 46 | 09/21/09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 34,799,702 | 32,017,440 ( 92.00 %) | 0 | 92.00 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.58% | 151M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- RAPT Stock
- Company RAPT Therapeutics, Inc.